Live Updates: COVID-19 Cases
  • World 30,826,118
    World
    Confirmed: 30,826,118
    Active: 7,428,228
    Recovered: 22,439,383
    Death: 958,507
  • USA 6,943,461
    USA
    Confirmed: 6,943,461
    Active: 2,545,409
    Recovered: 4,194,597
    Death: 203,455
  • India 5,351,723
    India
    Confirmed: 5,351,723
    Active: 1,016,032
    Recovered: 4,249,648
    Death: 86,043
  • Brazil 4,503,002
    Brazil
    Confirmed: 4,503,002
    Active: 577,828
    Recovered: 3,789,139
    Death: 136,035
  • Russia 1,097,251
    Russia
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 756,412
    Peru
    Confirmed: 756,412
    Active: 124,334
    Recovered: 600,795
    Death: 31,283
  • Mexico 688,954
    Mexico
    Confirmed: 688,954
    Active: 123,959
    Recovered: 492,192
    Death: 72,803
  • Spain 659,334
    Spain
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • South Africa 657,627
    South Africa
    Confirmed: 657,627
    Active: 54,926
    Recovered: 586,844
    Death: 15,857
  • Chile 444,674
    Chile
    Confirmed: 444,674
    Active: 14,319
    Recovered: 418,101
    Death: 12,254
  • France 428,696
    France
    Confirmed: 428,696
    Active: 305,873
    Recovered: 91,574
    Death: 31,249
  • Iran 419,043
    Iran
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 390,358
    UK
    Confirmed: 390,358
    Active: 348,599
    Recovered: ?
    Death: 41,759
  • Bangladesh 347,372
    Bangladesh
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 329,271
    Saudi Arabia
    Confirmed: 329,271
    Active: 15,383
    Recovered: 309,430
    Death: 4,458
  • Pakistan 305,031
    Pakistan
    Confirmed: 305,031
    Active: 6,572
    Recovered: 292,044
    Death: 6,415
  • Turkey 301,348
    Turkey
    Confirmed: 301,348
    Active: 27,786
    Recovered: 266,117
    Death: 7,445
  • Italy 296,569
    Italy
    Confirmed: 296,569
    Active: 43,161
    Recovered: 217,716
    Death: 35,692
  • Germany 271,672
    Germany
    Confirmed: 271,672
    Active: 19,206
    Recovered: 243,000
    Death: 9,466
  • Canada 142,745
    Canada
    Confirmed: 142,745
    Active: 9,362
    Recovered: 124,172
    Death: 9,211
  • Netherlands 91,934
    Netherlands
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,269
    China
    Confirmed: 85,269
    Active: 171
    Recovered: 80,464
    Death: 4,634
  • Australia 26,885
    Australia
    Confirmed: 26,885
    Active: 2,079
    Recovered: 23,962
    Death: 844
  • S. Korea 22,893
    S. Korea
    Confirmed: 22,893
    Active: 2,545
    Recovered: 19,970
    Death: 378
  • New Zealand 1,811
    New Zealand
    Confirmed: 1,811
    Active: 67
    Recovered: 1,719
    Death: 25

Remdesivir expected to be available for COVID-19 patients from next week

Author at TechGenyz Health
Remdesivir
A Conceptual Image Of Remdesivir Capsule.

Antiviral drug Remdesivir, approved by the US food and regulatory body for emergency use to treat the COVID-19 patients, is expected to be available by next week, the CEO of the company manufacturing the medicine has said.

The announcement was made on Sunday by Dan O’Day, CEO of Gilead Sciences, the pharmaceutical company making the vaccine.

The US is the worst-affected country in the world with over 1.1 million COVID-19 cases and more than 67,000 deaths, according to the Johns Hopkins University data.

The Food and Drug Administration (FDA) gave emergency use authorization (EUA) for the use of investigational Remdesivir to treat COVID-19 patients after some researches, including one led by Indian-American physician Aruna Subramanian, found that the drug helped recover some of the infected cases faster.

The EUA allows for Remdesivir to be distributed in the US and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe condition.

We intend to get that to patients in the early part of this next week, O’Day said on CBS’ Face of the Nation.

He said that his company has donated its entire available supply of Remdesivir, approximately 1.5 million vials, to the government, which can treat anywhere from 100,000 to 200,000 people.

O’Day said the government will determine which cities are most vulnerable and where the patients need this medicine.

Earlier, US President Donald Trump said that his administration has been working with the teams at the FDA, National Institute of Health and Gilead for spearheading this public-private partnership to make this happen very quickly.

In a statement, Gilead had earlier said that the EUA will facilitate broader use of Remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to the vaccine at additional hospitals across the country.

Remdesivir is authorized for the treatment of hospitalized patients with severe COVID-19 disease, it said, adding that the optimal duration of treatment is still being studied in ongoing clinical trials.

Under the EUA, both five-day and 10-day treatment durations are suggested, based on the severity of disease. The authorisation is temporary and does not take the place of the formal new drug application submission, review and approval process, Gilead noted.

Career

Subscribe